Actinic Keratosis (AK) and Cutaneous Squamous Cell Carcinoma (cSCC)

Inaugural Dermatology Innovation Symposium
October 15, 2022

Patrick K. Lee, MD

Professor & Vice Chair

Director, Dermatologic Surgery

Director, Micrographic Surgery and Dermatologic Oncology Fellowship

Department of Dermatology, University of California, Irvine

- I have no disclosures to reveal

Goals

- Epidemiology, pathogenesis, and clinical features of AK and cSCC
- Treatment modalities and management options
- cSCC: Advances in staging and prognostic assessment
- cSCC: Implications for treatment of advanced disease

AK

- Classic description: rough scaly papule on an erythematous base that develops in anatomic areas of high ultraviolet (UV) exposure
- Typically present in areas of highest solar damage in fair-skinned individuals
- Propensity for: head (esp scalp), ears, neck, dorsal aspects of arms and hands, lower extremities
- Overall, the rate in the United States is estimated to range from 11-26%; one source said 58 million in USA: 17%









AK – What is the issue?

- Estimates of the risk of progression of AK to SCC vary from less than 0.1% to 20%
- Limited follow-up in many studies makes precise prognosis difficult.
- Studies that have examined SCC histologically to look for adjacent contiguous AK have reported finding in more than 60% of cases
- Spontaneous regression rate of AKs highly variable, reported to be from 15% to 63% per year
- But AKs that spontaneously regress clinically reported to recur, with a recurrence rate estimated to be as high as 50% within the first year

Management – Procedural/In clinic

- Cryosurgery
- Chemical peel
- Curettage
- Photodynamic therapy
- Laser resurfacing

Management – Topical/At home

- 5-fluorouracil (5-FU) cream
- Diclofenac sodium gel
- Imiquimod cream
- Tirbanibulin ointment – KLYSIRI - microtubule inhibitor; 5 day course
- Ingenol mebutate – PICATO - withdrawn 10/2020

Cutaneous squamous cell carcinoma

Incidence, risk factors, diagnosis, and staging

Syril Keena T. Que, MD,[a] Fiona O. Zwald, MD,[b] and Chrysalyne D. Schmults, MD, MSCE[a]
Boston, Massachusetts, and Washington, District of Columbia

Learning objectives
After completing this learning activity, participants should be able to describe the incidence of cSCC and define factors that are independently associated with poor outcomes on multivariate analysis of cSCC; outline the various staging systems for cSCC, the features that upstage a cSCC, and the rate of local recurrence, metastatic disease, and disease specific death at each stage; and identify aggressive cSCC that require further work-up and treatment.

Disclosures
Editors
The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Authors
The authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Planners
The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Cutaneous squamous cell carcinoma (cSCC), a malignant proliferation of cutaneous epithelium, represents 20% to 50% of skin cancers. Although the majority of cSCCs are successfully eradicated by surgical excision, a subset of cSCC possesses features associated with a higher likelihood of recurrence, metastasis, and death. The proper identification of these aggressive cSCCs can guide additional work-up and management. In the first article in this continuing medical education series, we discuss the incidence, recurrence rates, mortality rates, and risk factors associated with cSCC and review the staging systems used to stratify patients

Cutaneous squamous cell carcinoma

Management of advanced and high-stage tumors

Syril Keena T. Que, MD,[a] Fiona O. Zwald, MD,[b] and Chrysalyne D. Schmults, MD, MSCE[a]
Boston, Massachusetts, and Washington, District of Columbia

Learning objectives
After completing this learning activity, participants should be able to evaluate evidence-based literature concerning cSCC preventive therapies; discuss general indications for Mohs surgery in the setting of cSCC; and work up high-risk cSCC and arrive at potential treatment options.

Disclosures
Editors
The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Authors
The authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Planners
The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

While the majority of cutaneous squamous cell carcinomas (cSCCs) can be treated surgically, the additional work-up and treatments indicated for high-risk cSCC remain undefined. In recent years, improvements in tumor staging systems have allowed for the more accurate stratification of tumors into high- and low-risk categories. This insight, along with the publication of cSCC guidelines, brings us closer to the development of a consensus approach. The second article in this continuing medical education series addresses in question and answer format the most common questions related to advanced and high-stage cSCCs, with a simplified flowchart. The questions include the following: 1) Does my patient have high-risk cSCC?; 2) What is the next step for patients with cSCC and palpable lymphadenopathy?; 3) In patients with no clinically evident lymphadenopathy, who are candidates for lymph node staging?; 4) What forms of radiologic imaging can help detect subclinical lymph node metastases?; 5) What is the role of sentinel lymph node biopsy in cSCC?;

Guidelines of care for the management of cutaneous squamous cell carcinoma

Work Group: Murad Alam, MD, (Co-Chair),[a] April Armstrong, MD, MPH,[b] Christian Baum, MD,[c] Jeremy S. Bordeaux, MD, MPH,[d] Marc Brown, MD,[e] Klaus J. Busam, MD,[f] Daniel B. Eisen, MD,[g] Vivek Iyengar, MD,[h] Clifford Lober, MD, JD,[i] David J. Margolis, MD, PhD,[j] Jane Messina, MD,[k,l] Alexander Miller, MD,[m] Stanley Miller, MD,[n] Eliot Mostow, MD, MPH,[o] Christen Mowad, MD,[p] Kishwer Nehal, MD,[q] Kristi Schmitt-Burr,[r] Aleksandar Sekulic, MD, PhD,[s] Paul Storrs, MD,[h] Joyce Teng, MD, PhD,[t] Siegrid Yu, MD,[u] Conway Huang, MD,[v] Kevin Boyer, MPH,[w] Wendy Smith Begolka, MBS,[w] and Christopher Bichakjian, MD, (Co-Chair)[x]

Invited Reviewers: John Y. S. Kim, MD,[y] Jeffrey H. Kozlow, MD, MS,[z] Bharat Mittal, MD,[aa] Jeffrey Moyer, MD,[bb] Thomas Olenecki, DO,[cc] and Phillip Rodgers, MD[dd]

Chicago and Schaumburg, Illinois; Denver, Colorado; Rochester, Minnesota; Cleveland, Rootstown, Burton, and Columbus, Ohio; Rochester and New York, New York; Sacramento, San Francisco, Yorba Linda, and Stanford, California; Kissimmee and Tampa, Florida; Philadelphia, Pennsylvania; Towson and Danville, Maryland; Phoenix, Arizona; Birmingham, Alabama; and Ann Arbor, Michigan.

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of human cancer and has an increasing annual incidence. Although most cSCC is cured with office-based therapy, advanced cSCC poses a significant risk for morbidity, impact on quality of life, and death. This document provides evidence-based recommendations for the management of patients with cSCC. Topics addressed include biopsy techniques and histopathologic assessment, tumor staging, surgical and nonsurgical management, follow-up and prevention of recurrence, and management of advanced disease. The primary focus of these recommendations is on evaluation and management of primary cSCC and localized disease, but where relevant, applicability to recurrent cSCC is noted, as is general information on the management of patients with metastatic disease. (J Am Acad Dermatol 2018;78:560-78.)

Non-melanoma skin cancer (NMSC)

- 3.5 million people per year in the United States, BCCs comprise of 80% of these cancers
- Not regularly recorded in cancer registries, making it difficult to determine accurate incidence rates in large populations.
- 2006: total number of NMSC in US population estimated to be 3,507,693; total number of people treated estimated at 2,152,500

Squamous Cell Carcinoma (SCC)

- Cutaneous squamous cell carcinoma (cSCC)
- cSCC 20% of skin malignancies, estimated annual incidence of 700,000
- Second most common skin cancer type also the second most common malignancy type
- Many cSCCs small low-risk cancers easily treated in physicians' offices by minor surgical procedures, some cSCCs can become problematic

Squamous Cell Carcinoma (SCC)

- Significant morbidity and cosmetic deformity can occur
- Metastases and death can ensue if the progression of cSCC is not halted
- 2012 estimate (Karia, et al): 5604 to 12,572 people developed nodal metastases and 3932 to 8791 people died from cSCC in the United States that year.
- “Rodney Dangerfield of skin cancer”

Squamous Cell Carcinoma (SCC)

- Similar to BCC
- Often Actinic Keratosis (AK) precursor
- Most occur on head, neck, and extremities - anatomic areas that receive the maximum amount of sunlight
- Most common in light-skin persons of western European descent
- Man to woman ratio of 3:1
- Incidence increases with age in both genders.
- Causes: also greater UV exposure as a consequence of ozone depletion, greater sun-seeking behavior and exposure, increased longevity of the population, etc

Pathogenesis and Etiology

- Molecular risk:
  - TP53, CDKN2A, Ras, NOTCH1
- Risk factors
  - Light skin (Fitzpatrick skin types I-III), age, male sex, exposure to sunlight or other ultraviolet radiation
  - Immunosuppression – solid organ transplants, 65-250 x, heart and lung > renal
  - Human papillomavirus (HPV) – 16, 18; 8, 9, 15 in transplants
  - Chronic scarring conditions, e.g. Marjolin's ulcer
  - Familial cancer syndromes
  - Environmental exposures – arsenic, ionizing radiation

SCC types – “Low risk”

- In situ – Bowen’s disease





SCC types

- Invasive



SCC types

- Keratoacanthoma



SCC types – “Higher risk”

- Adenoid/adenosquamous
- Spindle cell
- Desmoplastic







Diagnosis

- Biopsy
  - Shave
  - Punch?

Clinical Risk Factors for Aggressive Tumor Behavior—"High Risk" Cutaneous SCC

- Location – area H, dorsal hands, genitalia, mucous membranes
- Size - > 2 cm local recurrence doubles, metastasis triples
- Depth - > 4mm and/or through subQ fat, > 6 mm lip, >10 mm anywhere
- Poorly Defined Borders
- Rapid Growth
- Histologic Differentiation – poor differentiation
- Histologic Subtype
- Perineural Invasion

Clinical Risk Factors for Aggressive Tumor Behavior—“High Risk” Cutaneous SCC

- Neurological Symptoms and Signs
- Recurrence
- Scar Carcinoma (Marjolin Ulcer)
- Immunosuppression – overall >12% met
- History of Radiation Treatment

TABLE 2. Five-Year Recurrence and Metastatic Rates for Primary and Locally Recurrent cSCC as a Percentage of Determinate Cases*

Treatment Modality	*Local Recurrence Rate*	*Metastatic Rate*
Primary tumors of the skin (all modalities), %	N/A	5.2
Cryotherapy	N/A	N/A
ED&C	3.7	N/A
Surgical excision	8.1	N/A
Radiation therapy	10.0	N/A
Non-Mohs modalities	7.9	N/A
Mohs micrographic surgery	3.1	N/A
Non-sun-exposed skin/scar carcinoma (all modalities), %	N/A	37.9
Primary tumors of the lip (all modalities)	N/A	13.7
Non-Mohs modalities	10.5	N/A
Mohs micrographic surgery	2.3	N/A
Primary tumors of the ear (all modalities)	N/A	11.0
Non-Mohs modalities	18.7	N/A
Mohs micrographic surgery	5.3	N/A
Locally recurrent tumors (all modalities), %	N/A	30.3
Surgical excision	23.3	N/A
Mohs micrographic surgery	10.0	N/A
Recurrent tumors of the skin (all modalities), %	N/A	25.1
Recurrent tumors of the ear (all modalities), %	N/A	45.0
Recurrent tumors of the lip (all modalities), %	N/A	31.5

*Adapted from Rowe DE, et al. J Am Acad Dermatol. 1992; 26(6):976–90. Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.

N/A, data not available.

TABLE 3. Risk Factors Associated With Local Recurrence and Metastasis of cSCC

Tumor characteristics
Any cSCC in high-risk sites: central face, periocular region, eyelid, eyebrow, nose, perioral, lip (cutaneous and vermilion), chin, mandible, ear, preauricular, postauricular, and temple
cSCC >1-cm diameter in intermediate-risk sites: cheeks, forehead, scalp, and neck
cSCC >2-cm diameter in any site
Poorly defined borders
cSCC exhibiting rapid growth
Neurologic symptoms
Locally recurrent cSCC after primary therapy
Histology
Depth >4 mm
Poorly differentiated
Aggressive histologic patterns: adenoid (acantholytic), desmoplastic, or spindle-cell cSCC, and invasive Bowen disease carcinoma
Perineural or vascular invasion
Host factors
Sites or previous radiation therapy
Exogenous immunosuppression (medications)
Endogenous immunosuppression (lymphoproliferative disorder, HIV)
Arising in scars or chronic wounds
Arising in sites of chronic inflammation
Genetic propensity for cSCC: XP

Goals of SCC treatment

- (1) to completely extirpate the tumor
- (2) to minimize the risk of recurrence and metastasis
- (3) to restore normal function after treatment
- (4) to provide the best possible aesthetic outcome

Treatment options

- Curettage and Electrodesiccation (C and D, ED & C) – small, low risk, < 1 cm trunk, arms, legs; beware of Bowen's disease
- Cryotherapy – similar to above
- Standard Surgical Excision (SSE) –
  - well-circumscribed tumors < 2 cm not on the ears, lips, eyelids, nose, or scalp and do not invade the fat - margins of 4 to 6mm; > 2 cm, 9 mm or greater

Treatment options

- Mohs Micrographic Surgery (MMS)


11:37
Cancer Type
APPENDIX
Basal Cell Carcinoma
Squamous Cell Carcinoma
Lentigo Maligna
Melanoma in situ
Other


Carrier
12:06 AM
Cancer Type
Location
Restart
Area H
?
Face (central face, eyelids [including inner/outer canthi], eyebrows, nose, lips [cutaneous/ mucosal/vermillion], chin, ear and periauricular skin/sulci, temple)
Genitalia (including perineal and perianal), Nipples/areola, Hands, Feet, Ankles, Nail units
Appropriate Use
Appendix


11:37
Area
APPENDIX
Area H
?
Area M
?
Area L
-
Trunk, Extremities (excluding pretibial surface, hands, feet, nail units, and ankles)


AT&T
12:24 PM
Subtype
Score
Restart
MOHS SURGERY IS
APPROPRIATE
The use of Mohs is appropriate for the specific indication and is generally considered acceptable.
MEDIAN SCORE
1 2 3 4 5 6 7 8 9
SELECTED CRITERIA
Squamous Cell Carcinoma
Area H
Recurrent
Aggressive
Appropriate Use
Appendix

TABLE 4. Appropriate Use Criteria for the Treatment of cSCC by Mohs Micrographic Surgery[110]

*Tumor Type**	*Area H*	*Area M*	*Area L*
Primary cSCC with no high-risk† features healthy patients	Mohs appropriate	Mohs appropriate	Mohs appropriate (if >2.0 cm)‡
Primary SCC with no high-risk† features immunocompromised patients	Mohs appropriate	Mohs appropriate	Mohs appropriate (if >1 cm)‡
Verrucous cSCC healthy and immunocompromised patients	Mohs appropriate	Not assessed	Not assessed
SCC, KA type healthy patients	Mohs appropriate	Mohs appropriate	Mohs appropriate (if >1.0 cm)‡
cSCC, KA type immunocompromised patients	Mohs appropriate	Mohs appropriate	Mohs appropriate (if >0.5 cm)
cSCCIS/Bowen disease carcinoma healthy patients	Mohs appropriate	Mohs appropriate	Mohs appropriate (if >2.0 cm)‡
cSCCIS/Bowen disease carcinoma immunocompromised	Mohs appropriate	Mohs appropriate	Mohs appropriate (if >1.0 cm)‡
Recurrent cSCC (all types) or other high-risk features† healthy or immunocompromised patients	Mohs appropriate	Mohs appropriate	Mohs appropriate‡§
Aggressive (high risk) cSCC† healthy and immunocompromised patients	Mohs appropriate	Mohs appropriate	Mohs appropriate

Area H: central face, ears, genitalia, hands, feet, pretibial.

Area M: cheeks, forehead, scalp, neck.

Area L: trunk, extremities except hands, feet, pretibial.

*Tumor type excludes actinic keratosis and cSCCis–non-Bowen disease type.

†Aggressive cSCC indicates tumors with high-risk histologic features including the following: sclerosing, basosquamous, small cell, poorly or undifferentiated, spindle cell, pagetoid, infiltrating, KA (centrofacial), single cell, clear cell, lymphoepithelial, sarcomatoid, Breslow depth 2 mm or greater and Clark level IV or greater.

‡Mohs surgery is indicated for any size tumor with special patient features including the following: previous radiated skin, genetic syndromes, osteomyelitis, a history of aggressive-behaving tumors, chronic ulcer, inflammation, and traumatic scar.

§Except for cSCCis–Bowen disease type (Bowen disease carcinoma) ≤2.0 cm.

Treatment options

- Radiation therapy
  - Electron beam
  - Brachytherapy
- Topical therapies – not approved in US
  - 5-fluorouracil
  - Imiquimod
- Photodynamic therapy (PDT) – approved for AK's, multiple studies for cSCC, mostly in situ

Classification

- The American Joint Committee on Cancer's (AJCC) most recent staging system, AJCC-8, published in October 2016, uses tumor diameter ≥2 cm as the distinguishing factor between T1 and T2 tumors
- High-risk features in AJCC-8 staging, which result in upstaging to T3, include tumor diameter ≥4 cm, minor bone erosion, invasion of nerves 0.1 mm in caliber or in subcutis, or deep invasion (≥6 mm or beyond the subcutaneous fat)
- T4 is reserved for major bone involvement or skull base invasion

Table I. American Joint Committee on Cancer (AJCC) cutaneous SCC staging system for tumors of the head and neck skin 8th edition

T category	T criteria	N category	N criteria for pathologic N	M category	M criteria
TX	Primary tumor cannot be identified	NX	Regional lymph nodes cannot be assessed	M0	No distant metastasis
Tis	Carcinoma in situ	N0	No regional lymph node metastasis	M1	Distant metastasis
T1	Tumor <2 cm in greatest dimension	N1	Metastasis in a single ipsilateral lymph node, ≤3 cm in greatest dimension and ENE^{-}*		
T2	Tumor ≥2 cm but <4 cm in greatest dimension	N2	Metastasis in a single ipsilateral lymph node ≤3 cm in greatest dimension and ENE^{+}; or >3 cm but not >6 cm in greatest dimension and ENE^{-}; or metastases in multiple ipsilateral lymph nodes, none >6 cm in greatest dimension and ENE^{-}; or in bilateral or contralateral lymph nodes, none >6 cm in greatest dimension and ENE^{-}		
T3	Tumor ≥4 cm in clinical diameter OR minor bone erosion OR perineural invasion OR deep invasion†	N2a	Metastasis in single ipsilateral or contralateral node ≤3 cm in greatest dimension and ENE^{+}; or in a single ipsilateral node >3 cm but not >6 cm in greatest dimension and ENE^{-}		
T4	Tumor with gross cortical bone/marrow, skull base invasion, and/or skull base foramen invasion	N2b	Metastasis in multiple ipsilateral nodes, none >6 cm in greatest dimension and ENE^{-}		
T4a	Tumor with gross cortical bone/marrow invasion	N2c	Metastasis in bilateral or contralateral lymph nodes, none >6 cm in greatest dimension and ENE^{-}		
T4b	Tumor with skull base invasion and/or skull base foramen involvement	N3	Metastasis in a lymph node >6 cm in greatest dimension and ENE^{-}; or in a single ipsilateral node >3 cm in greatest dimension and ENE^{+}; or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE^{+}		
		N3a	Metastasis in a lymph node >6 cm in greatest dimension and ENE^{-}		
		N3b	Metastasis in a single ipsilateral node >3 cm in greatest dimension and ENE^{+}; or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE^{+}		

TABLE 1. AJCC TNM Staging Classification for cSCC (Seventh Edition, 2010)

	Primary Tumor (T)
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ
T1	Tumor 2 cm or less in greatest dimension with less than 2 high-risk features*
T2	Tumor greater than 2 cm in greatest dimension or tumor any size with 2 or more high-risk features†
T3	Tumor with invasion of maxilla, mandible, orbit, or temporal bone
T4	Tumor with invasion of skeleton (axial or appendicular) or perineural invasion of skull base
	Regional Lymph Nodes (N)
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
N2	Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
N2a	Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
N2b	Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
N2c	Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
N3	Metastasis in a lymph node, more than 6 cm in greatest dimension
	Distant Metastasis (M)
M0	No distant metastasis
M1	Distant metastasis

Anatomic Stage/Prognostic Groups

Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T3	N0	M0
	T1	N1	M0
	T2	N1	M0
	T3	N1	M0
Stage IV	T1	N2	M0
	T2	N2	M0
	T3	N2	M0
	T any	N3	M0
	T4	N any	M0
	T any	N any	M1

Histologic Grade (G)

GX	Grade cannot be assessed
G1	Well differentiated
G2	Moderately differentiated
G3	Poorly differentiated
G4	Undifferentiated

Classification

- The Brigham and Women's Hospital (BWH) staging system contains a high-risk T2b category, which requires the presence of ≥2 risk factors and includes only about 5% of cSCCs but accounts for 72% of nodal metastases and 83% of deaths from cSCC

Table II. Brigham and Women's Hospital tumor staging system

Stage	No. of high-risk factors*
T1	0
T2a	1
T2b	2-3
T3	≥4

*Brigham and Women's Hospital high-risk factors include tumor diameter ≥2 cm, poorly differentiated histology, perineural invasion ≥0.1 mm, or tumor invasion beyond the subcutaneous fat (excluding bone invasion which automatically upgrades tumor to Brigham and Women's Hospital stage T3).

Advanced Disease

- Work-up:
  - AJCC-8 stage T4, BWH stage T2b/T3
  - Lymphadenopathy – palpable or non
  - Radiologic lymph node staging
  - Sentinel Lymph Node Biopsy (SLNB)


High-risk SCC*
BWH stage T2b/T3
AJCC-8 stage T4
Palpable lymphadenopathy
No palpable lymph nodes
Ultrasound-guided FNA or biopsy confirmation of lymph node metastasis
CT of lymph node basin
Positive
Negative
Positive
Negative
Lymph node biopsy
Consider SLNB or ultrasound
Positive
Negative
Positive
Negative
CT q4-6months for 2 years** for radiologic monitoring
Lymphadenectomy ± ART of lymph node basin ± chemotherapy
Consider CT or serial ultrasound q4-6 months for 2 years for continued nodal surveillance

Advanced Disease

- Therapies:
  - Adjuvant Radiation Therapy (ART)?
  - Adjuvant chemotherapy - 5-fluorouracil(5-FU)/cisplatin, 5-FU/carboplatin, paclitaxel/carboplatin combinations
  - Epidermal growth factor receptor inhibitors (EGFR) – cetuximab, off-label
  - Antiprogrammed cell death protein 1 Inhibitors (PD-1)

Table I. Indications for consideration of advanced workup and adjuvant therapy in high-risk cutaneous squamous cell carcinoma*

Management strategy	Stage/risk factors for consideration
Imaging	BWH: T2b and T3; AJCC-8: T2, T3, or T4; CT to assess for nodal involvement or bony invasion; MRI to assess for tumor size and depth of invasion, nerve invasion, and central nervous system involvement; and PET/CT to evaluate for nodal and distant metastases
Sentinel lymph node biopsy or ultrasonography of the nodal basin	BWH: T2b and T3; AJCC-8: T4
Adjuvant radiation therapy	Surgical margins positive or unclear; high risk of local recurrence; marked single-cell tumor spread at periphery; lymphovascular invasion; in-transit metastasis; invasion of large-caliber nerves (≥0.1 mm), multiple nerves; where there is concern about surgical margins, named nerves; and in combination with lymphadenectomy, for lymph node metastases
Chemotherapy, EGFR inhibitors, and immune checkpoint therapy	Locoregional cSCC not controlled by surgery or radiation; distant metastases

AJCC-8, American Joint Committee on Cancer, 8th edition; *BWH*, Brigham and Women's Hospital; *cSCC*, cutaneous squamous cell carcinoma; *CT*, computed tomography; *EGFR*, epidermal growth factor receptor; *MRI*, magnetic resonance imaging; *PET*, positron emission tomography.

*Current data are insufficient to provide firm recommendations. The table above provides options for consideration as we await controlled trials.

Follow-up

- >75% of cSCC recurrences occur within 2 years after initial diagnosis
- Low-stage every 6 months for the first few years after diagnosis
- High-stage (BWH T2b cases) patients every 4 months for skin and lymph node examinations
- Particularly high risk for recurrence, repeat imaging (MRI for cases of named nerve invasion; CT of the nodal basin for metastatic concern) every 6 months for 2 years posttreatment may be considered.

Table II. Topical therapies for cutaneous squamous cell carcinoma chemoprevention and treatment

Therapy	Indications	Frequency of application	Mechanism of action	Adverse effects	Level of evidence*
Topical retinoids[47-50]	Ineffective at preventing cSCC according to VA randomized chemoprevention trial,[50] but other studies show decrease in AK count	N/A	Induces apoptosis of tumor cells; downregulate proliferative keratins K6 and K16	Burning, irritation, erythema, and dermatitis	IB
5-fluorouracil[80,81]	Approved by the FDA in 1970 for treatment of AKs; off-label use: treatment of cSCC in situ	AK: 0.5% cream: apply once daily for up to 4 weeks; 5% cream: apply twice daily for 2-4 weeks cSCC in situ: 5% cream: apply twice daily for 3 to 6 weeks; treatment can be continued for ≤10-12 weeks	Pyrimidine analogue: cytotoxic metabolites are incorporated into DNA and RNA, inducing cell cycle arrest and apoptosis	Erythema, shallow erosions, pruritus, dermatitis, burning sensation, and photosensitivity	AK: IA; cSCC in situ: IB
Imiquimod[82,83]	Approved by the FDA for the treatment of AKs; not practical for treatment of field disease because can have significant side effects when applied to large surface areas	AK: Aldara†—apply 2 times/week × 16 weeks Zyclara†—treatment consists of 2 cycles (14 days each) separated by 1 rest period (14 days) with no treatment	Induces, synthesizes, and releases cytokines, thereby inducing secretion of interferon-gamma by naïve T cells	Local reactions: erythema, discomfort, erosion, and dyschromia Systemic symptoms: flu-like symptoms, dizziness, headache, and, rarely, urinary retention	AK: IA; cSCC in situ: IB
Ingenol mebutate[84]	Treatment of AKs	Face or scalp: apply 0.015% gel once daily to affected area for 3 consecutive days Trunk or extremities: apply 0.05% gel once daily to affected area for 2 consecutive days	Multiple mechanisms of action, including direct cell death and protein kinase C–mediated inflammatory response	Severe allergic reactions; herpes zoster; eye pain; periorbital edema; headache; mild to moderate erythema, scaling, and dryness	AK: IB
Diclofenac[85]	Treatment of AKs	Apply 3% gel to lesion area twice daily for 60-90 days	Nonsteroidal antiinflammatory drug that reduces the production of prostaglandins by inhibiting inducible cyclooxygenase-2	Pruritus, rash, desquamation, elevated liver function tests, flu-like symptoms, and headache	IB
Photodynamic therapy[53-56]	Treatment of AKs	Various protocols	Exogenous photosensitizer and light source induces a porphyria; neoplastic cells accumulate more porphyrins than normal cells	Erythema, blistering, desquamation, and discomfort	IB

AK, Actinic keratosis; *FDA*, US Food and Drug Administration; *cSCC*, squamous cell carcinoma; *N/A*, not applicable; *VA*, Veterans Affairs.

*Level IA evidence includes evidence from metaanalysis of randomized controlled trials; level IB evidence includes evidence from ≥1 randomized controlled trial; level IIA evidence includes evidence from ≥1 controlled study without randomization; level IIB evidence includes evidence from ≥1 other type of experimental study; level III evidence includes evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; and level IV evidence includes evidence from expert committee reports or opinions or clinical experience of respected authorities, or both.

†Aldara, 3M Health Care Limited, Loughborough, England; Zyclara, Valeant Pharmaceuticals North America LLC, Bridgewater, NJ.

Table III. Oral and systemic agents for cutaneous squamous cell carcinoma chemoprevention

Therapy	Indications	Dosing	Mechanism of action	Adverse effects	Level of evidence*
Nicotinamide[66-70]	Off-label use: decreases AKs and SCCs; can be used by anyone for chemoprophylaxis	500 mg PO BID	Amide form of vitamin B_3; enhances the repair of UV light–induced DNA damage; also reduces the level of immunosuppression induced by UV light	None reported; liver failure at high doses (>3 mg/d)	IB
Oral retinoids[58-64]	Off-label uses: cSCC prevention in xeroderma pigmentosum and organ transplant patients; consider in patients who develop 5-10 cSCCs per year; consider for patients on BRAF inhibitors with multiple cSCCs	High-dose isotretinoin (2 mg/kg/d); acitretin 10-30 mg PO daily	Natural or synthetic analogues of vitamin A; bind to specific nuclear receptors and involved in immunomodulation, induction of apoptosis, cell cycle control, inhibition of ornithine decarboxylase, and inhibition of cellular proliferation and keratinization	Dry skin and mucosa, alopecia, increased liver transaminases and triglycerides, decreased night vision, and teratogenicity	IB
Capecitabine[71-73]	Solid organ transplant recipients with multiple cSCCs	950 mg/m^2 on days 1-14 of a 21-day cycle along with 3 times weekly subcutaneous interferon alfa	Converted to active form, 5-FU, in the body	Fatigue, nausea, hand–foot syndrome, gout, and decreased renal function	III
Aspirin and NSAIDs[86]	Preventive effect shown in meta-analysis; however, unclear if benefits worth the potential adverse effects	Variable NSAIDs and dosing frequencies studied	Inhibits COX-2, which results in decreased inflammation and apoptosis of neoplastic cells	Gastrointestinal ulcers and bleeding, kidney failure, nausea, rash, headache, and dizziness	IA
Sirolimus[75-79]	Solid organ transplant recipients—studies show decreased risk of cSCC compared to calcineurin inhibitors	Varies	Inhibits the mammalian target of rapamycin, thereby reducing the growth and proliferation of tumor cells	Myelosuppression, hyperlipidemia, increased susceptibility to infection, peripheral edema, hypertension, headache, rash, and abdominal pain	IB

5-FU, 5-fluorouracil; *AK*, actinic keratosis; *BID*, twice daily; *COX-2*, cyclooxygenase-2; *cSCC*, cutaneous squamous cell carcinoma; *NSAID*, nonsteroidal antiinflammatory drug; *PO*, orally; *UV*, ultraviolet light.

*Level IA evidence includes evidence from metaanalysis of randomized controlled trials; level IB evidence includes evidence from ≥1 randomized controlled trial; level IIA evidence includes evidence from ≥1 controlled study without randomization; level IIB evidence includes evidence from ≥1 other type of experimental study; level III evidence includes evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; and level IV evidence includes evidence from expert committee reports or opinions or clinical experience of respected authorities, or both.